{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:53:52Z","timestamp":1758635632824,"version":"3.40.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T00:00:00Z","timestamp":1381968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/hr.2013.140","type":"journal-article","created":{"date-parts":[[2013,10,17]],"date-time":"2013-10-17T06:14:20Z","timestamp":1381990460000},"page":"194-201","source":"Crossref","is-referenced-by-count":9,"title":["Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats"],"prefix":"10.1038","volume":"37","author":[{"given":"Facundo Mart\u00edn","family":"Bertera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julieta Sof\u00eda","family":"Del Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Lovera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Chiappetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel H\u00e9ctor","family":"Polizio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alberto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"H\u00f6cht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,17]]},"reference":[{"key":"BFhr2013140_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.coph.2012.12.002","volume":"13","author":"PM Vanhoutte","year":"2013","unstructured":"Vanhoutte PM, Gao Y . Beta blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol 2013; 13: 265\u2013273.","journal-title":"Curr Opin Pharmacol"},{"key":"BFhr2013140_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/FJC.0b013e3182073e27","volume":"59","author":"Y Gao","year":"2012","unstructured":"Gao Y, Vanhoutte PM . Nebivolol: an endothelium-friendly selective \u03b21-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59: 16\u201321.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFhr2013140_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrcardio.2013.1","volume":"10","author":"G Parati","year":"2013","unstructured":"Parati G, Ochoa JE, Lombardi C, Bilo G . Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10: 143\u2013155.","journal-title":"Nat Rev Cardiol"},{"key":"BFhr2013140_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1046\/j.1440-1681.2001.03508.x","volume":"28","author":"DF Su","year":"2001","unstructured":"Su DF, Miao CY . Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol 2001; 28: 709\u2013715.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFhr2013140_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11906-011-0201-3","volume":"13","author":"PM Rothwell","year":"2011","unstructured":"Rothwell PM . Does blood pressure variability modulate cardiovascular risk? Curr Hypertens Rep 2011; 13: 177\u2013186.","journal-title":"Curr Hypertens Rep"},{"key":"BFhr2013140_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/hr.2011.104","volume":"34","author":"AE Schutte","year":"2011","unstructured":"Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT, Malan L . Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: the SABPA Study. Hypertens Res 2011; 34: 1127\u20131134.","journal-title":"Hypertens Res"},{"key":"BFhr2013140_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1161\/HYPERTENSIONAHA.111.175752","volume":"58","author":"G Schillaci","year":"2001","unstructured":"Schillaci G, Pucci G, Parati G . Blood pressure variability: an additional target for antihypertensive treatment? Hypertension 2001; 58: 133\u2013135.","journal-title":"Hypertension"},{"key":"BFhr2013140_CR8","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1100\/tsw.2002.814","volume":"2","author":"LA Fortepiani","year":"2002","unstructured":"Fortepiani LA, Ort\u00edz MC, Atucha NM, Garc\u00eda-Esta\u00f1 J . Nebivolol ameliorates nitric oxide deficient hypertension. ScientificWorldJournal 2002; 2: 1676\u20131684.","journal-title":"ScientificWorldJournal"},{"key":"BFhr2013140_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1211\/jpp.62.07.0010","volume":"62","author":"CA Di Verniero","year":"2010","unstructured":"Di Verniero CA, Bertera F, Buontempo F, Bernabeu E, Chiappetta D, Mayer MA, Bramuglia GF, Taira CA, H\u00f6cht C . Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension. J Pharm Pharmacol 2010; 62: 890\u2013900.","journal-title":"J Pharm Pharmacol"},{"key":"BFhr2013140_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1006\/jmcc.1999.1071","volume":"32","author":"I Bern\u00e1tov\u00e1","year":"2000","unstructured":"Bern\u00e1tov\u00e1 I, Pech\u00e1nov\u00e1 O, Pelouch V, Simko F . Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 2000; 32: 177\u2013185.","journal-title":"J Mol Cell Cardiol"},{"key":"BFhr2013140_CR11","first-page":"1","volume":"7","author":"LD Aimone","year":"2005","unstructured":"Aimone LD . Overview of pharmacokinetics. Curr Protoc Pharmacol 2005; 7: 1\u201326.","journal-title":"Curr Protoc Pharmacol"},{"key":"BFhr2013140_CR12","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1203\/01.PDR.0000127012.37315.36","volume":"55","author":"P Pladys","year":"2004","unstructured":"Pladys P, Lahaie I, Cambonie G, Thibault G, Le NL, Abran D, Nuyt AM . Role of brain and peripheral angiotensin II in hypertension and altered arterial baroreflex programmed during fetal life in rat. Pediatr Res 2004; 55: 1042\u20131049.","journal-title":"Pediatr Res"},{"key":"BFhr2013140_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.autneu.2008.01.001","volume":"139","author":"HC Souza","year":"2008","unstructured":"Souza HC, Martins-Pinge MC, Dias da Silva VJ, Borghi-Silva A, Gastaldi AC, Blanco JH, Tezini GC . Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton Neurosci 2008; 139: 38\u201345.","journal-title":"Auton Neurosci"},{"key":"BFhr2013140_CR14","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D . Pharmacokinetics, 2nd edn. Marcel Dekker: New York. 1982."},{"key":"BFhr2013140_CR15","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/ndt\/gfr449","volume":"27","author":"NC Moningka","year":"2012","unstructured":"Moningka NC, Tsarova T, Sasser JM, Baylis C . Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade. Nephrol Dial Transplant 2012; 27: 913\u2013920.","journal-title":"Nephrol Dial Transplant"},{"key":"BFhr2013140_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/01.HYP.20.3.298","volume":"20","author":"MO Ribeiro","year":"1992","unstructured":"Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R . Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 1992; 20: 298\u2013303.","journal-title":"Hypertension"},{"key":"BFhr2013140_CR17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-3565(25)22055-9","volume":"227","author":"N Terao","year":"1983","unstructured":"Terao N, Shen DD . Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 1983; 227: 369\u2013375.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFhr2013140_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF03258259","volume":"3","author":"A Van Peer","year":"1992","unstructured":"Van Peer A, Snoeck E, Woestenborghs R, Van de Velde V, Mannens G, Meuldermans W, Heykants J . Clinical pharmacokinetics of nebivolol. Drug Invest 1992; 3: 25\u201330.","journal-title":"Drug Invest"},{"key":"BFhr2013140_CR19","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00210-012-0756-9","volume":"385","author":"FM Bertera","year":"2012","unstructured":"Bertera FM, Del Mauro JS, Polizio AH, Chiappetta D, Taira CA, H\u00f6cht C . Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 833\u2013843.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFhr2013140_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/00005344-198805000-00007","volume":"11","author":"A Van de Water","year":"1988","unstructured":"Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PA . Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552\u2013563.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFhr2013140_CR21","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00210-006-0078-x","volume":"373","author":"C H\u00f6cht","year":"2006","unstructured":"H\u00f6cht C, Di Verniero C, Opezzo JA, Bramuglia GF, Taira CA . Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 2006; 373: 310\u2013318.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFhr2013140_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00210-011-0698-7","volume":"385","author":"FM Bertera","year":"2012","unstructured":"Bertera FM, Del Mauro JS, Chiappetta D, Polizio AH, Buontempo F, Taira CA, H\u00f6cht C . Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 325\u2013335.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"BFhr2013140_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1527-3466.2004.tb00138.x","volume":"22","author":"A Kuroedov","year":"2004","unstructured":"Kuroedov A, Cosentino F, L\u00fcscher TF . Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004; 22: 155\u2013168.","journal-title":"Cardiovasc Drug Rev"},{"key":"BFhr2013140_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s002280050194","volume":"51","author":"A Himmelmann","year":"1996","unstructured":"Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J . Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996; 51: 259\u2013264.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFhr2013140_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1590\/S0100-879X2006005000077","volume":"40","author":"VC Biancardi","year":"2007","unstructured":"Biancardi VC, Bergamaschi CT, Lopes OU, Campos RR . Sympathetic activation in rats with L-NAME-induced hypertension. Braz J Med Biol Res 2007; 40: 401\u2013408.","journal-title":"Braz J Med Biol Res"},{"key":"BFhr2013140_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/01.hjh.0000198042.24257.bf","volume":"24","author":"DJ Campbell","year":"2006","unstructured":"Campbell DJ . L-NAME hypertension: trying to fit the pieces together. J Hypertens 2006; 24: 33\u201336.","journal-title":"J Hypertens"},{"key":"BFhr2013140_CR27","first-page":"H2267","volume":"268","author":"A Zanchi","year":"1995","unstructured":"Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR, Waeber B . Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol 1995; 268: H2267\u2013H2273.","journal-title":"Am J Physiol"},{"key":"BFhr2013140_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/01.HYP.26.4.691","volume":"26","author":"M Sander","year":"1995","unstructured":"Sander M, Hansen PG, Victor RG . Sympathetically mediated hypertension caused by chronic inhibition of nitric oxide. Hypertension 1995; 26: 691\u2013695.","journal-title":"Hypertension"},{"key":"BFhr2013140_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1470320312470580","volume":"14","author":"W Yan","year":"2013","unstructured":"Yan W, Sheng ZM, Yu L . Nebivolol treatment improves resistant arterial function and reduces ventricular hypertrophy and angiotensin II in spontaneously hypertension rats. J Renin Angiotensin Aldosterone Syst 2013; 14: 146\u2013155.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFhr2013140_CR30","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/HJH.0b013e328356766f","volume":"30","author":"J Varagic","year":"2012","unstructured":"Varagic J, Ahmad S, Voncannon JL, Moniwa N, Simington SW Jr, Brosnihan BK, Gallagher PE, Habibi J, Sowers JR, Ferrario CM . Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens 2012; 30: 1766\u20131774.","journal-title":"J Hypertens"},{"key":"BFhr2013140_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10557-004-6224-0","volume":"18","author":"JA Chiladakis","year":"2004","unstructured":"Chiladakis JA, Georgiopoulou E, Alexopoulos D . Autonomic effects of nebivolol versus atenolol in healthy subjects. Cardiovasc Drugs Ther 2004; 18: 469\u2013473.","journal-title":"Cardiovasc Drugs Ther"},{"key":"BFhr2013140_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejphar.2005.02.003","volume":"511","author":"G Sacco","year":"2005","unstructured":"Sacco G, Evangelista S, Criscuoli M, Goso C, Bigioni M, Binaschi M, Manzini S, Maggi CA . Involvement of nitric oxide in both central and peripheral haemodynamic effect of D\/L-nebivolol and its enantiomers in rats. Eur J Pharmacol 2005; 511: 167\u2013174.","journal-title":"Eur J Pharmacol"},{"key":"BFhr2013140_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1440-1681.2007.04588.x","volume":"34","author":"HM Stauss","year":"2007","unstructured":"Stauss HM . Identification of blood pressure control mechanisms by power spectral analysis. Clin Exp Pharmacol Physiol 2007; 34: 362\u2013388.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFhr2013140_CR34","doi-asserted-by":"publisher","first-page":"H62","DOI":"10.1152\/ajpcell.1995.269.1.C163","volume":"269","author":"BJ Janssen","year":"1995","unstructured":"Janssen BJ, Oosting J, Slaaf DW, Persson PB, Struijker-Boudier HA . Hemodynamic basis of oscillations in systemic arterial pressure in conscious rats. Am J Physiol 1995; 269: H62\u2013H71.","journal-title":"Am J Physiol"},{"key":"BFhr2013140_CR35","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1152\/japplphysiol.01142.2007","volume":"104","author":"R Fazan Jr","year":"2008","unstructured":"Fazan R Jr, Huber DA, Silva CA, Dias da Silva VJ, Salgado MC, Salgado HC . Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 2008; 104: 1683\u20131689.","journal-title":"J Appl Physiol"},{"key":"BFhr2013140_CR36","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(10)60235-8","volume":"375","author":"AJ Webb","year":"2010","unstructured":"Webb AJ, Fischer U, Mehta Z, Rothwell PM . Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 2010; 375: 906\u2013915.","journal-title":"Lancet"},{"key":"BFhr2013140_CR37","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1474-4422(10)70066-1","volume":"9","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Howard SC, Dolan E, O\u2019Brien E, Dobson JE, Dahl\u00f6f B, Poulter NR, Sever PS, ASCOT-BPLA and MRC Trial Investigators. Effects of beta-blockers and calcium channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469\u2013480.","journal-title":"Lancet Neurol"},{"key":"BFhr2013140_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1517\/17425250903397381","volume":"6","author":"C H\u00f6cht","year":"2010","unstructured":"H\u00f6cht C, Bertera FM, Mayer MA, Taira CA . Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol 2010; 6: 199\u2013211.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"BFhr2013140_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1586\/ecp.10.44","volume":"3","author":"C H\u00f6cht","year":"2010","unstructured":"H\u00f6cht C, Bertera FM, Taira CA . Importance of blood pressure variability in the assessment of cardiovascular risk and benefits of antihypertensive therapy. Expert Rev Clin Pharmacol 2010; 3: 617\u2013621.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"BFhr2013140_CR40","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1212\/WNL.0b013e31822b007a","volume":"77","author":"AJ Webb","year":"2011","unstructured":"Webb AJ, Fischer U, Rothwell PM . Effects of b-blocker selectivity on blood pressure variability and stroke: a systematic review. Neurology 2011; 77: 731\u2013737.","journal-title":"Neurology"},{"key":"BFhr2013140_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/hr.2012.209","volume":"36","author":"FM Bertera","year":"2013","unstructured":"Bertera FM, Del Mauro JS, Lovera V, Chiappetta D, H\u00e9ctor Polizio A, Alberto Taira C, H\u00f6cht C . Acute effects of third generation \u03b2-blockers on short-term and beat-to-beat blood pressure variability in sinoaortic-denervated rats. Hypertens Res 2013; 36: 349\u2013355.","journal-title":"Hypertens Res"},{"key":"BFhr2013140_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1440-1681.2005.04229.x","volume":"32","author":"DS Wang","year":"2005","unstructured":"Wang DS, Xie HH, Shen FM, Cai GJ, Su DF . Blood pressure variability, cardiac baroreflex sensitivity and organ damage in experimentally hypertensive rats. Clin Exp Pharmacol Physiol 2005; 32: 545\u2013552.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"BFhr2013140_CR43","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1097\/00004872-199917110-00004","volume":"17","author":"J Blanc","year":"1999","unstructured":"Blanc J, Ponchon P, Laude D, Elghozi JL, Jover B . Blood pressure variability in established L-NAME hypertension in rats. J Hypertens 1999; 17: 1527\u20131534.","journal-title":"J Hypertens"},{"key":"BFhr2013140_CR44","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/j.1476-5381.1996.tb16008.x","volume":"119","author":"O Gou\u00e9dard","year":"1996","unstructured":"Gou\u00e9dard O, Blanc J, Gaudet E, Ponchon P, Elghozi JL . Contribution of the renin-angiotensin system to short-term blood pressure variability during blockade of nitric oxide synthesis in the rat. Br J Pharmacol 1996; 119: 1085\u20131092.","journal-title":"Br J Pharmacol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr2013140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2013140","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr2013140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T17:20:15Z","timestamp":1746033615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr2013140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,17]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFhr2013140"],"URL":"https:\/\/doi.org\/10.1038\/hr.2013.140","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"type":"print","value":"0916-9636"},{"type":"electronic","value":"1348-4214"}],"subject":[],"published":{"date-parts":[[2013,10,17]]}}}